Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap
Ivonescimab is expected to become the world's first bispecific drug combining immunotherapy and anti-angiogenesis.
- Ivonescimab is expected to become the world's first bispecific drug combining immunotherapy and anti-angiogenesis.
- Potential initiation of a Phase III clinical trial for manfidokimab (IL-4R) for the treatment of moderate atopic dermatitis.
- Over the next five years, Akeso has high expectations of launching around 10 internally developed blockbuster drugs, both in China and worldwide, thereby achieving successful commercialization.
- Akeso has established and continuously advances its integrated and efficient system of discovery, development, production, and sales of its innovative drugs and pipeline candidates.